GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » 3-Year RORE %

CERo Therapeutics Holdings (CERo Therapeutics Holdings) 3-Year RORE % : 0.00% (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. CERo Therapeutics Holdings does not have enough data to calculate 3-Year RORE %.


CERo Therapeutics Holdings 3-Year RORE % Historical Data

The historical data trend for CERo Therapeutics Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings 3-Year RORE % Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
3-Year RORE %
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
3-Year RORE % - -

Competitive Comparison of CERo Therapeutics Holdings's 3-Year RORE %

For the Biotechnology subindustry, CERo Therapeutics Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's 3-Year RORE % falls into.



CERo Therapeutics Holdings 3-Year RORE % Calculation

CERo Therapeutics Holdings's 3-Year RORE % for the quarter that ended in Dec. 2022 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2022 and 3-year before.


CERo Therapeutics Holdings  (NAS:CERO) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


CERo Therapeutics Holdings 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines